載入中
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
前收盤價
US$19.00
+US$0.88 · +4.86%
盤中時間採用ET。市場資料可能有所延遲。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日內區間
目前US$19.00
52週區間
目前US$19.00
盤中時間採用ET。市場資料可能有所延遲。
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
日內區間
目前US$19.00
52週區間
目前US$19.00
| 項目（USD） | 2025會計年度 |
|---|---|
| 營收 | 297.6萬 USD |
| 毛利 | 297.6萬 USD |
| 研究與開發 | 1.27億 USD |
| 銷售、一般及管理費用 | 3751.6萬 USD |
| 營業費用 | 1.64億 USD |
| 利息收入 | 634.8萬 USD |
| 利息支出 | 1.7萬 USD |
| 折舊和攤銷 | 491.1萬 USD |
| 營業利益 | −1.61億 USD |
| 淨利 | −1.49億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$39.00
上漲空間 105.26%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1302.25萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM782.33萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF442.74萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO163.93萬0.01%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA151.9萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares Micro-Cap ETFIWC95萬0.07%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 ETFVTWO29.14萬0.00%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Broad Market ETFSCHB23.01萬0.00%453.77億 USD0.03%US$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOSchwab U.S. Broad Market ETFSCHBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
